Back HIV Populations Transgender People

Transgender People

IDWeek 2013: HIV+ Transwomen Not Getting the Maximum Benefits of Care

More than three-quarters of HIV positive transgender women in San Franciscowere linked to care and 65% are taking antiretroviral therapy (ART), but only 44% achieve viral suppression, according to findings presented* at the recent Second IDWeek conference in San Francisco and in the American Journal of Public Health. A larger national survey, however, found that 68% of transgender people reached undetectable viral load.

alt

Read more:

HIV Treatment Outcomes Improving among Transgender People

Transgender people with HIV are now doing as well on antiretroviral therapy (ART) as other patients and achieving similar outcomes, according to a retrospective analysis published in the May 30, 2013, advance edition of Clinical Infectious Diseases.

alt

Read more:

CDC Fact Sheets on HIV among Women and Transgender People

The U.S. Centers for Disease Control and Prevention (CDC) recently announced the availability of an updated fact sheet on HIV among Women, as well as a new fact sheet on HIV among Transgender People.alt

Read more:

The Stigma-Sickness Slope: HIV Vulnerability in Asian Transgender Populations

As many as half of all transgender people in Asia may be living with HIV, according to a new report by the United Nations Development Programme and the Asia Pacific Transgender Network. The findings offer insight into the altmultifactorial drivers of high HIV seroprevalence and vulnerability among trans persons in the region.

Read more:

IAS 2011: iPrEx Shows PrEP is Durable [VIDEO]

The effectiveness of biomedical approaches to prevent HIV infection was a key theme of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), held July 17-20, 2011, in Rome.

Among the major studies presented, Robert Grant from the Gladstone Institute of the University of California at San Francisco described final data from the iPrEx trial, which showed that pre-exposure prophylaxis (PrEP) using tenofovir/emtricitabine (Truvada) reduced new HIV infections by 42% overall, and by more than 90% among people who demonstrated good adherence.alt

Read more: